Teva to Pay $1.2 Billion to Resolve FTC Pay for Delay Lawsuit

Updated on

Teva Pharmaceutical Industries Ltd. has agreed to pay $1.2 billion in a settlement with the U.S. Federal Trade Commission resolving claims that Cephalon Inc., which Teva acquired in 2012, blocked generic drug competition.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.